NCT02694588View on ClinicalTrials.gov

Clinical and Molecular Phenotyping in IBD

NACompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

October 31, 2018

Study Completion Date

December 31, 2021

Conditions
IBD
Interventions
DRUG

Infliximab

HD-endoscopy, CLE, endoscopic ultrasound after application of TNF alpha antibody

DRUG

Vedolizumab

HD-endoscopy, CLE, endoscopic ultrasound after application of Anti-Integrin antibody

Trial Locations (1)

24105

Medical Department I, University Hospital Schleswig-Holstein, Kiel

All Listed Sponsors
lead

University Hospital Schleswig-Holstein

OTHER

NCT02694588 - Clinical and Molecular Phenotyping in IBD | Biotech Hunter | Biotech Hunter